<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250727</url>
  </required_header>
  <id_info>
    <org_study_id>2000023826</org_study_id>
    <nct_id>NCT04250727</nct_id>
  </id_info>
  <brief_title>Switching to Potential Reduced Exposure Products in Adult Smokers</brief_title>
  <acronym>JUUL</acronym>
  <official_title>Switching to Potential Reduced Exposure Products: Examining Feasibility, Acceptability, and Harm Reduction in Cigarette Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the feasibility, acceptability, and the potential harm reduction of
      switching to potentially lower risk, non-combustible tobacco products in adult smokers. Part
      One of this study aims to assess the interest of current smokers in switching to an
      e-cigarette device (i.e. JUUL) compared to alternative non-combustible tobacco products (i.e.
      smokeless tobacco/snus) and/or medicinal nicotine via survey. Part Two will consist of a
      pilot study of 50 non-treatment seeking adult smokers with medical co-morbidities to
      investigate within-person changes in smoking behavior as a result of switching to different
      concentrations a nicotine salt electronic cigarette product (i.e. JUUL, 3% and 5% nicotine
      concentration). Additionally, by measuring bio-markers of tobacco exposure from baseline,
      this will allow the study to assess the potential for harm reduction in switching from
      cigarettes to an e-cigarette device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>50 current non-treatment seeking adult smokers will be randomized to either the 3% or 5% nicotine concentration JUUL condition.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who switched from cigarettes to the JUUL.</measure>
    <time_frame>This will be evaluated at week 8.</time_frame>
    <description>We will investigate whether switching behavior varies by the 3% and 5% nicotine concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of biomarkers (nicotine, NNAL, CO) among smokers with medical co-morbidities</measure>
    <time_frame>Change from baseline to week 8 will be assessed.</time_frame>
    <description>Participants will provide repeated lab samples for biomarker assessments. Urine and breath carbon monoxide samples will be obtained at baseline, week 4, and week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Cigarette Evaluation Scale</measure>
    <time_frame>These assessments will occur at week 8.</time_frame>
    <description>To evaluate the acceptability of switching, participants will rate JUUL and how it compares to their preferred cigarettes. Additionally, participants will also be asked how likely it is that they will continue to use JUUL compared to cigarettes.We will utilize items modified from the Modified Cigarette Evaluation Scale adapted for e-cigarettes for these subjective measures.To evaluate the feasibility of switching to JUUL, we will document how many participants switch entirely to JUUL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <condition>E-Cigarette Use</condition>
  <condition>Smoking Behaviors</condition>
  <condition>Harm Reduction</condition>
  <condition>Inflammatory Markers</condition>
  <condition>Toxic Effect of Tobacco and Nicotine</condition>
  <condition>Carcinogenesis</condition>
  <arm_group>
    <arm_group_label>3% Nicotine Concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 participants will be randomly assigned to receive a JUUL with 3% nicotine concentration JUULpods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% Nicotine Concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 participants will be randomly assigned to receive a JUUL with 5% nicotine concentration JUULpods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUUL</intervention_name>
    <description>50 current non-treatment seeking adult smokers will be switched from smoking cigarettes to the JUUL device and JUUL pods containing either 3% or 5% concentration nicotine salts.</description>
    <arm_group_label>3% Nicotine Concentration</arm_group_label>
    <arm_group_label>5% Nicotine Concentration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 years old(in line with NIH guidelines for 18+ being the age of consent in
             adults) (2008 PHS Guideline Update Panel)

          2. English literate

          3. Smoke at least 5 cigarettes per day for the past 6 months

          4. Expired breath carbon monoxide level â‰¥ 6ppm at baseline or detected urine cotinine
             level with NicAlert test strip

          5. Not currently interested in smoking cessation services or quitting

          6. Not interested in the use of existing FDA-approved tobacco pharmacotherapies (i.e.,
             NRT, wellbutrin, varenicline).

          7. Medical co-morbidity (i.e., hypertension, diabetes, asthma, COPD/emphysema,
             cardiovascular disease, stroke, cancer, HIV)

        Exclusion Criteria:

          1. Currently using any stop smoking treatments (2008 PHS Guideline Update Panel)

          2. History of serious psychiatric condition (i.e., bipolar disorder, schizophrenia)

          3. Current uncontrolled medical condition

          4. Cardiac conditions that required a hospitalization or intensive treatment on an
             outpatient basis in the past year including: myocardial infarction, coronary artery
             disease, unstable angina, congestive heart failure, or tachyarrhythmias (including
             rapid atrial fibrillation, ventricular tachycardia, or ventricular fibrillation)

          5. Current use of drugs identified by urine drug screen or other tobacco products
             identified by self-report

          6. Female participants of child-bearing age will be excluded if they are currently
             pregnant or breastfeeding or report an unwillingness to use effective birth control
             (i.e., abstinence, IUD, implant, sterilization, pill, patch, ring, or barrier method
             such as condoms) for the duration of the study

          7. Severe lung disease that requires supplemental oxygen

          8. History of vaping cannabis products in the past 3 months or positive drug screen for
             THC

          9. Uncontrolled asthma (&lt;20 on the Asthma Control Test (ACT) or requiring steroids more
             than 1x per year)

         10. Unstable COPD: defined as GOLD category C or D (more than 2 exacerbations or 1
             exacerbation leading to hospitalization in the past year)

         11. ECG showing ischemic changes or tachyarrhythmias

         12. Planning to quit smoking with a set goal or time for quit attempt

         13. Known hypersensitivity to propylene glycol

         14. Patients with an FEV1 &lt; 40%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Fucito, Ph.D.</last_name>
    <phone>203-200-1470</phone>
    <email>lisa.fucito@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Fucito, Ph.D.</last_name>
      <phone>203-200-1470</phone>
      <email>lisa.fucito@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Berg CJ, Haardoerfer R, Escoffery C, Zheng P, Kegler M. Cigarette users' interest in using or switching to electronic nicotine delivery systems for smokeless tobacco for harm reduction, cessation, or novelty: a cross-sectional survey of US adults. Nicotine Tob Res. 2015 Feb;17(2):245-55. doi: 10.1093/ntr/ntu103. Epub 2014 Jun 20.</citation>
    <PMID>24951496</PMID>
  </reference>
  <reference>
    <citation>Brawley OW, Glynn TJ, Khuri FR, Wender RC, Seffrin JR. The first Surgeon General's report on smoking and health: the 50th anniversary. CA Cancer J Clin. 2014 Jan-Feb;64(1):5-8. doi: 10.3322/caac.21210. Epub 2013 Nov 18.</citation>
    <PMID>24249254</PMID>
  </reference>
  <reference>
    <citation>Brenner DR, Scherer D, Muir K, Schildkraut J, Boffetta P, Spitz MR, Le Marchand L, Chan AT, Goode EL, Ulrich CM, Hung RJ. A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1729-51. doi: 10.1158/1055-9965.EPI-14-0064. Epub 2014 Jun 24. Review.</citation>
    <PMID>24962838</PMID>
  </reference>
  <reference>
    <citation>Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007 May;32(5):912-23. Epub 2006 Jul 27.</citation>
    <PMID>16875787</PMID>
  </reference>
  <reference>
    <citation>Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, Stone AA. PROMIS Fatigue Item Bank had Clinical Validity across Diverse Chronic Conditions. J Clin Epidemiol. 2016 May;73:128-34. doi: 10.1016/j.jclinepi.2015.08.037. Epub 2016 Mar 3.</citation>
    <PMID>26939927</PMID>
  </reference>
  <reference>
    <citation>Chang CM, Edwards SH, Arab A, Del Valle-Pinero AY, Yang L, Hatsukami DK. Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop. Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302. doi: 10.1158/1055-9965.EPI-16-0675. Epub 2016 Nov 9.</citation>
    <PMID>28151705</PMID>
  </reference>
  <reference>
    <citation>Jamal A, Phillips E, Gentzke AS, Homa DM, Babb SD, King BA, Neff LJ. Current Cigarette Smoking Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59. doi: 10.15585/mmwr.mm6702a1.</citation>
    <PMID>29346338</PMID>
  </reference>
  <reference>
    <citation>Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001 Feb;3(1):7-16.</citation>
    <PMID>11260806</PMID>
  </reference>
  <reference>
    <citation>Delnevo CD, Giovenco DP, Steinberg MB, Villanti AC, Pearson JL, Niaura RS, Abrams DB. Patterns of Electronic Cigarette Use Among Adults in the United States. Nicotine Tob Res. 2016 May;18(5):715-9. doi: 10.1093/ntr/ntv237. Epub 2015 Nov 2.</citation>
    <PMID>26525063</PMID>
  </reference>
  <reference>
    <citation>FagerstrÃ¶m KO. Can reduced smoking be a way for smokers not interested in quitting to actually quit? Respiration. 2005 Mar-Apr;72(2):216-20. Review.</citation>
    <PMID>15824536</PMID>
  </reference>
  <reference>
    <citation>Grace RC, Kivell BM, Laugesen M. Gender differences in satisfaction ratings for nicotine electronic cigarettes by first-time users. Addict Behav. 2015 Nov;50:140-3. doi: 10.1016/j.addbeh.2015.06.027. Epub 2015 Jun 12.</citation>
    <PMID>26135334</PMID>
  </reference>
  <reference>
    <citation>Heatherton TF, Kozlowski LT, Frecker RC, FagerstrÃ¶m KO. The FagerstrÃ¶m Test for Nicotine Dependence: a revision of the FagerstrÃ¶m Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.</citation>
    <PMID>1932883</PMID>
  </reference>
  <reference>
    <citation>Hecht SS. Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers. Chem Res Toxicol. 2017 Jan 17;30(1):367-375. doi: 10.1021/acs.chemrestox.6b00372. Epub 2016 Dec 1. Review.</citation>
    <PMID>28092948</PMID>
  </reference>
  <reference>
    <citation>Hughes JR. The hardening hypothesis: is the ability to quit decreasing due to increasing nicotine dependence? A review and commentary. Drug Alcohol Depend. 2011 Sep 1;117(2-3):111-7. doi: 10.1016/j.drugalcdep.2011.02.009. Epub 2011 Mar 15. Review.</citation>
    <PMID>21411244</PMID>
  </reference>
  <reference>
    <citation>Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986 Mar;43(3):289-94.</citation>
    <PMID>3954551</PMID>
  </reference>
  <reference>
    <citation>Irwin DE, Atwood CA Jr, Hays RD, Spritzer K, Liu H, Donohue JF, Leidy NK, Yount SE, DeWalt DA. Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations. Qual Life Res. 2015 Apr;24(4):999-1009. doi: 10.1007/s11136-014-0818-1. Epub 2014 Oct 12.</citation>
    <PMID>25307510</PMID>
  </reference>
  <reference>
    <citation>King BA, Patel R, Nguyen KH, Dube SR. Trends in awareness and use of electronic cigarettes among US adults, 2010-2013. Nicotine Tob Res. 2015 Feb;17(2):219-27. doi: 10.1093/ntr/ntu191. Epub 2014 Sep 19.</citation>
    <PMID>25239961</PMID>
  </reference>
  <reference>
    <citation>Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis. 2003 Sep;7(9):811-9. Review.</citation>
    <PMID>12971663</PMID>
  </reference>
  <reference>
    <citation>Morean ME, Krishnan-Sarin S, Sussman S, Foulds J, Fishbein H, Grana R, O'Malley SS. Psychometric Evaluation of the E-cigarette Dependence Scale. Nicotine Tob Res. 2019 Oct 26;21(11):1556-1564. doi: 10.1093/ntr/ntx271.</citation>
    <PMID>29301008</PMID>
  </reference>
  <reference>
    <citation>Patel D, Davis KC, Cox S, Bradfield B, King BA, Shafer P, Caraballo R, Bunnell R. Reasons for current E-cigarette use among U.S. adults. Prev Med. 2016 Dec;93:14-20. doi: 10.1016/j.ypmed.2016.09.011. Epub 2016 Sep 7.</citation>
    <PMID>27612572</PMID>
  </reference>
  <reference>
    <citation>Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016 Jan 28;1:15004. doi: 10.1038/sigtrans.2015.4. eCollection 2016. Review.</citation>
    <PMID>29263891</PMID>
  </reference>
  <reference>
    <citation>Popova L, Ling PM. Alternative tobacco product use and smoking cessation: a national study. Am J Public Health. 2013 May;103(5):923-30. doi: 10.2105/AJPH.2012.301070. Epub 2013 Mar 14.</citation>
    <PMID>23488521</PMID>
  </reference>
  <reference>
    <citation>Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE Jr. The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J Clin Epidemiol. 2014 May;67(5):516-26. doi: 10.1016/j.jclinepi.2013.10.024.</citation>
    <PMID>24698295</PMID>
  </reference>
  <reference>
    <citation>Shadel WG, Edelen MO, Tucker JS, Stucky BD, Hansen M, Cai L. Development of the PROMIS nicotine dependence item banks. Nicotine Tob Res. 2014 Sep;16 Suppl 3:S190-201. doi: 10.1093/ntr/ntu032.</citation>
    <PMID>25118226</PMID>
  </reference>
  <reference>
    <citation>Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, Feng J, Wang L, West R. Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med. 2017 Mar 21;166(6):390-400. doi: 10.7326/M16-1107. Epub 2017 Feb 7.</citation>
    <PMID>28166548</PMID>
  </reference>
  <reference>
    <citation>Sobell, L., &amp; Sobell, M. (1995). Alcohol consumption measures. In J. Allen &amp; M. Columbus (Eds.), Assessing alcohol problems: A guide for clinicians and researcher (pp. 55-73). Bethesda, MD: National Institute on Alcohol Abuse &amp; Alcoholism.</citation>
  </reference>
  <reference>
    <citation>Sobell, L., &amp; Sobell, M. (2003). Alcohol consumption measures. In J. P. A. a. V. B. &amp; Wilson (Eds.), Assessing alcohol problems: A guide for clinicians and researchers. (pp. 75-99). Bethesda, MD: National Institute on Alcohol Abuse &amp; Alcoholism.</citation>
  </reference>
  <reference>
    <citation>Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017 Aug 31;7(1):10255. doi: 10.1038/s41598-017-10925-7.</citation>
    <PMID>28860576</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinogenesis</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

